Enantioselective modulatory effects of naringenin enantiomers on the expression levels of miR-17-3p involved in endogenous antioxidant defenses

Article abstract of DOI:10.3390/nu9030215

Naringenin is a flavanone present in citrus fruit as a mixture of chiral isomers. The numerous biological properties attributed to this compound include antioxidant and anti-inflammatory activities, even though the molecular mechanisms of these remain unknown. This study aims to evaluate the effects of racemic and enantiomeric naringenin on the expression levels of miR-17-3p, miR-25-5p and relative mRNA targets, to elucidate the mechanisms underlying these antioxidant and anti-inflammatory properties. Caco-2 cells, a well characterized in vitro model which mimics the intestinal barrier, were treated with subtoxic concentrations of racemate and enantiomers. The expression levels of miR-17-3p and miR-25-5p were determined by Real-Time PCR and were found to be decreased for both miRNAs. miR-17-3p behavior was in agreement with the increased levels of target mRNAs coding for two antioxidant enzymes, manganese-dependent superoxide dismutase (MnSOD) and glutathione peroxidase 2 (GPx2), while expression levels of miR-25-5p were not in agreement with its target mRNAs, coding for two pro-inflammatory cytokines, Tumor necrosis factor-alpha (TNF-α) and Interleukin-6 (IL-6). These results lead to the conclusion that naringenin could exert its antioxidant activity through epigenetic regulation operated by miRNAs, while anti-inflammatory activity is regulated by other miRNAs and/or mechanisms.

Full text of DOI:10.3390/nu9030215

nutrients
Article
Enantioselective Modulatory Effects of Naringenin
Enantiomers on the Expression Levels of miR-17-3p
Involved in Endogenous Antioxidant Defenses
Valeria Curti 1,2, Arianna Di Lorenzo 1,2, Daniela Rossi 1, Emanuela Martino 3, Enrica Capelli 3,
Simona Collina 1 and Maria Daglia 1,
*
1
Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section,
Pavia University, Viale Taramelli 12, 27100 Pavia, Italy; valeria.curti86@hotmail.it or
valeriacurti@kolinpharma.com (V.C.); arianna.dilorenzo01@universitadipavia.it or
ariannadilorenzo@kolinpharma.com (A.D.L.); daniela.rossi@unipv.it (D.R.); simona.collina@unipv.it (S.C.)
KOLINPHARMA S.p.A., Lainate, Corso Europa 5, 20020 Lainate, Italy
2
3
Department of Earth and Environmental Sciences, University of Pavia, Via S. Epifanio 14, 27100 Pavia, Italy;
emanuela.martino@unipv.it (E.M.); enrica.capelli@unipv.it (E.C.)
*
Correspondence: maria.daglia@unipv.it; Tel.: +39-0382987388
Received: 28 November 2016; Accepted: 24 February 2017; Published: 28 February 2017
Abstract: Naringenin is a flavanone present in citrus fruit as a mixture of chiral isomers.
The numerous biological properties attributed to this compound include antioxidant and
anti-inflammatory activities, even though the molecular mechanisms of these remain unknown.
This study aims to evaluate the effects of racemic and enantiomeric naringenin on the expression
levels of miR-17-3p, miR-25-5p and relative mRNA targets, to elucidate the mechanisms underlying
these antioxidant and anti-inflammatory properties. Caco-2 cells, a well characterized in vitro model
which mimics the intestinal barrier, were treated with subtoxic concentrations of racemate and
enantiomers. The expression levels of miR-17-3p and miR-25-5p were determined by Real-Time
PCR and were found to be decreased for both miRNAs. miR-17-3p behavior was in agreement with
the increased levels of target mRNAs coding for two antioxidant enzymes, manganese-dependent
superoxide dismutase (MnSOD) and glutathione peroxidase 2 (GPx2), while expression levels of
miR-25-5p were not in agreement with its target mRNAs, coding for two pro-inflammatory cytokines,
Tumor necrosis factor-alpha (TNF-α) and Interleukin-6 (IL-6). These results lead to the conclusion that
naringenin could exert its antioxidant activity through epigenetic regulation operated by miRNAs,
while anti-inflammatory activity is regulated by other miRNAs and/or mechanisms.
Keywords: naringenin racemate; naringenin enantiomers; antioxidant enzymes; pro-inflammatory
cytokines; caco-2 cells; microRNA; epigenetics
1. Introduction
Naringenin (5,7,4-thihydroxyflavanone) is a chiral flavonoid belonging to the class of flavanones.
It is widely distributed in fruits of Citrus species, especially in grapefruit (Citrus paradisi Macfad.) and
oranges (Citrus sinensis (L.) Osbeck), as well as tomatoes (Solanum lycopersicum L.) [
naringenin is mainly found bound to glucose (naringenin-7-O-glucoside, also called prunin) [
rutinose (naringenin-7-O-rutinoside, narirutin), and rhamnose (naringenin 7-rhamnoglucoside,
naringin) [ ]. In grapefruit, naringin content depends on the variety and ranges from 115 to
384 mg/L [ ]. In tomatoes, naringenin is mainly found in its free form (ranging from 0.8 to 4.2 mg/100 g
of whole red tomato) [ ]. When naringenin is present as an aglycone, it occurs as a mixture of
1
,2
]. In Citrus fruits,
3],
4
5
2
enantiomers whose ratio depends on the ripeness of the fruit and the purification methods used to
isolate the isomers [6,7].
Nutrients 2017, 9, 215; doi:10.3390/nu9030215
www.mdpi.com/journal/nutrients

Nutrients 2017, 9, 215
2 of 13
A number of in vitro studies have shown that naringenin possesses many physiological and
pharmacological activities such as antioxidant and anti-inflammatory activities, which have been most
studied, and hepatoprotective, anti-mutagenic and anticancer effects [1,6,8,9]. Thus, its bioavailability
must be seen as a key aspect affecting its subsequent in vivobiological activity. Many studies have
shown the presence of naringenin in both urine and in plasma following the intake of naringin, either
alone or as part of Citrus fruit juices [10–12]. Despite the high rate of absorption that occurs especially
at gut level, the naringenin bioavailability is poor, and this may be due to the first-pass effect and
hepatic metabolism [13–15].
Despite its poor bioavailability, in vivo studies have shown that naringenin possesses
anti-inflammatory and antioxidant capacities. Chtourou et al., in 2016, showed that administration
of naringenin at a dose of 50 mg/body weight in rats previously exposed for 90 days to a high
cholesterol diet, led to the restoration of both enzymatic and non-enzymatic antioxidant defenses
(i.e., superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), nonprotein sulfhydryl
groups (NPSH), glutathione (GSH), Vitamin C and Vitamin E) [16]. Ozkaya et al. showed that
naringenin supplementation (50 mg/body weight) on the hepatic damage induced by lead (Pb) in
rats increased CAT and GPx concentrations in groups of rats treated with naringenin and lead acetate,
than in those treated with lead acetate alone [17]. Furthermore, Liu et al. have demonstrated that
naringenin, administered at doses of both 25 and 50 mg/body weight/day, reduced oxidative stress in
cardiorenal syndrome in a rat model. A similar increase was found in the mRNA levels coding for
Nrf2 (a well known transcription factor regulating antioxidant response), and GCLc (regulating the
glutathione synthesis), underling that naringenin acts on transcription activity [18].
Moreover, recently, Chtourou et al. [19] showed that naringenin is able to decrease
pro-inflammatory mediators such as TNF-α, IL-6 and IL-1b in rats, and suggested that its
anti-inflammatory activity could be due to the inhibition of NF-kB, a signal transduction pathway
that promotes the transcription of gene coding for pro-inflammatory proteins. Recent studies
have demonstrated that naringenin also possesses anti-inflammatory properties in the gut [20
,21].
(R) naringenin was found to be the most effective enantiomer in reducing TNF- and IL-6 levels
α
in human peripheral blood mononuclear cells (hPMBC). These results demonstrate that the
anti-inflammatory effect of naringenin is enantioselective and that (R) naringenin is the eutomer [7].
Many studies have shown that polyphenols also modify gene expression by acting on the
regulation of epigenetic mechanisms. They are able to modulate DNA methylation, hystonic
modifications and microRNA (miRNA) expression [22]. miRNAs are small non-coding RNAs
with an average length of 22 nucleotides, which control various biological processes such as
cell development, differentiation, proliferation and apoptosis [23–29]. Literature data show that
miR-17-3p and miR-25-5p are involved in the oxidative stress and inflammatory response, respectively.
miR-17-3p has three mRNA targets coding for mitochondrial antioxidant enzymes (manganese
superoxide dismutase (MnSOD), glutathione peroxidase-2 (GPx2), and thioredoxin reductase-2
(TrxR2)) [30]. miR-17-3p has been found to be regulated by different polyphenols, such as resveratrol
and quercetin [31,32]. Our previous studies, which involved treating ECV-304 (human vascular
endothelial cells) and hPBMC cells with increasing subtoxic concentrations of methyl 3-O-methyl
gallate, demonstrated that this polyphenol induces an underexpression of miR-17-3p, and relative
upregulation of target mRNA expression levels [33], placing this molecular mechanism at the base
of the antioxidant effects registered in both in vitro and in vivostudies [34]. As far as miR-25-5p is
concerned, it is strictly involved in the inflammatory response and its over or down regulation is
associated with changes in cytokine levels during the inflammation process [35,36]. Few articles
have been published on the capacity of naringenin to modulate miRNA expression to date. In 2012,
Milenkovic et al. [37] reported that nutritional doses of naringenin resulted in a modification of miRNA
expression levels in mouse liver. Taken together, these results make naringenin and its enantiomers
promising candidates in risk prevention against the occurrence of inflammatory-based diseases, such as
inflammatory bowel diseases.

Nutrients 2017, 9, 215
3 of 13
Thus, considering: (a) the bioavailability of naringenin, albeit modest; (b) its involvement
in the modulation of oxidative stress and inflammatory response (especially at the intestinal
level); (c) the different activities exerted by naringenin enantiomers; and (d) its capacity to
modulate the expression of some miRNAs, the aim of this investigation was to study the molecular
mechanisms underlying the effects of racemic and enantiomeric naringenin on oxidative stress and the
anti-inflammatory response, in which miR-17-3p and miR-25-5p play a key role.
2. Materials and Methods
2.1. Reagents and Instruments
(R/S) Naringenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one) was obtained from
Sigma-Aldrich (Milan, Italy). The HPLC grade solvents used as eluents were obtained from
Merck-VWR (Milan, Italy). Analytical chiral resolutions were performed with a Jasco system
consisting of a AS-2055 plus autosampler, a PU-2089 plus pump and a MD-2010 plus multi-wavelength
detector coupled with a CD-2095 plus circular dichroism detector (Jasco Europe S.r.l., Cremella,
LC, Italy). The preparative separations were carried out on an HPLC apparatus produced by Varian
Chromatographic Systems (Walnut Creek, CA, USA), which consists of two Rainin SD-1 pumps with
500 mL/min pump heads, a 410 Varian autosampler, a 320 Varian Prostar UV-detector and a 320 Varian
fraction collection module. A DIP 1000 photoelectric polarimeter from Jasco (JASCO Europe, Cremella,
LC, Italy) was used for [α] measurements that were recorded at room temperature using a 1 dm cell
and a sodium lamp.
MiRNeasy Mini kit was purchased from Qiagen GmbH (Hilden, Germany). A Quant-it RNA
HS was purchased from Invitrogen (Grand Island, NY, USA). A Brilliant III Ultra-Fast SYBR® Green
RT-PCR Master Mix was purchased from Agilent Technologies (Santa Clara, CA, USA).
2.2. Naringenin Enantioresolution
The chiral resolution of naringenin was performed via preparative enantioselective
chromatography employing a Chiralpak® AD column (500 mm
Chiral Technologies Europe (Illkirch, France) according to Gaggeri et al. [ ].Enantiomeric resolution
×
50 mm I.D., dp = 20
8
µm),
in g-scale was achieved, eluting with methanol at room temperature with a flow rate of 40 mL/min.
The partitioning of the eluate was effected according to the UV profile (detection at 290 nm) and
the analytical in-process control of collected fractions performed using a Chiralpak AD-H column
(
250 mm × 4.6 mm ID; dp = 5
µm) eluting with methanol (flow rate 1 mL/min, UV detector at 290 nm).
Accordingly, the fractions containing the enantiomers were evaporated at 334 mbar and 40 ◦C and
dried in a vacuum oven at 0.1 mbar and 25 ◦C, furnishing2.1 g of (
−
)-(S) naringenin, ([α]D25
=
−
28.7◦,
c = 0.36% in ethanol, ee = 96%) and 1.8 g of (+)-(R) naringenin ([α]2D5 = +22.8◦, c = 0.30% in ethanol,
ee = 94%).
2.3. Cell Culture and Treatments
Human colon adenocarcinoma (CaCo-2) cells were purchased from the American Type Culture
Collection (Rockville, MD, USA). The cells were cultured in D-MEM supplemented with 10% fetal
bovine serum, L-glutamine (2 mM), 100 IU/mL penicillin◦and 100
µg/mL streptomycin (all from
Invitrogen Co., Paisley, Scotland, UK). Cells were grown at 37 C in a humidified atmosphere containing
5% CO2. The treatments were performed for 24 h with different concentrations of racemate and (S)
and (R) enantiomers, with the concentration of DMSO never exceeding 0.4%.
2.4. MTT Assay
Cell viability was detected by MTT assay, testing a wide range of doses of racemate and (S) and
(R) naringenin enantiomers (i.e., from 1 to 1000
µg/mL). In brief, cells were seeded into permeable
polyester membrane filter supports (Transwell, 12-mm diameter, 0.4-mm pore size; Corning Costar) at

Nutrients 2017, 9, 215
4 of 13
a density of 0.25
well was calculated relative to that of control cells.
×
106 cells/cm2. After a 24 h incubation period, the percentage of viable cells in each
2.5. RNA Extraction and Quantitative Real Time PCR (RT-PCR)
Total RNA was extracted from cells using the miRNeasy Mini kit (Qiagen, Hilden, Germany),
according to the manufacturer’s instructions. The quality of RNA was assessed by gel electrophoresis
using denaturing agarose gel 1.2%. Quantitative RNA analysis was performed using a fluorimetric
method by means of the QubitR 2.0 platform (Invitrogen, Grand Island, NY, USA) using the Quant-iT
RNA HS Assay with the following conditions: 2
obtained by mixing 1 L of Qubit RNA HS reagent to 199
real-time PCR (RT-PCR) was done using cDNA obtained by a reverse transcription reaction using the
miRCURY LNA Universal RT micro RNA PCR kit: 4 L of total RNA (5 ng/ L) was added to 4
of 5 reaction buffer, 2 L of enzyme mix, 1 L of synthetic spike-in and 9 L of nuclease free water.
µL of RNA was added to 198
µL of working solution
µ
™
µ
L of Qubit RNA HSbuffer. Quantitative
™
™
µ
µ
µL
×
µ
µ
µ
The mixture was then incubated in a thermo cycler (SureCycler 8800-Agilent Technologies, Santa Clara,
California) at 42 ◦C for 60 min, 95 ◦C for 5 min, and then immediately cooled to 4 ◦C. To evaluate the
expression of miR-17-3p and 25-5p, RT-PCR reactions were performed with the AriaMX Real Time
PCR System (Agilent Technologies, Santa Clara, California) using the Universal cDNA Synthesis and
SYBRGreen Master Mix kits (Exiqon (Qiagen), Hilden, Germany). PCR amplification was performed
in a 10
and 1
µL reaction mixture containing 4 µL of 1:80 diluted cDNA, 5 µL of SYBR Green master mix,
µL of specific LNA p◦robes (Exiqon, (Qiagen), Hilden, Germany) using the following reaction
◦
conditions: a first step at 95 C for 10 min, 45 amplification cycles of 95 C for 10 s followed by a step at
60 ◦C for 1 min. U6 small nuclear RNA (snU6) was used to normalize the expression data of miRNAs
and every assay was performed in triplicate. To evaluate the levels of mRNA coding for MnSOD,
GPx2 and TrxR2, which are validated targets of miR-17-3p, and of TNF-a and IL-6, which are targets of
miR-25-5p,RT-PCR reactions were performed with the AriaMX Real Time PCR System using Brilliant
III Ultra-Fast SYBR® Green RT-PCR Master Mix (Agilent Santa Clara, California) according to the
manufacturer’s protocol. Primers were designed using Primer-BLAST software (available online on
27 February 2017: http://www.ncbi.nlm.nih.gov/tools/primer-blast). The sequences for the used
primers were:
MnSOD forward: 50-AAACCTCAGCCCTAACGGTG-30
MnSOD reverse: 50-CCAGGCTTGATGCACATCTTA-30
GPx2 forward: 50-GAGGTGAATGGGCAGAACGA-30
GPx2 reverse: 50-CTCTGCAGTGAAGGGGACTG-30
TNF-α forward: 50-CCTCTCTGCCATCAAGAGCC-30
TNF-α reverse: 50-TTGAGTAACTTCGCCTGCGT-30
IL-6 forward: 50-GTCCAGTTGCCTTCTCCCTG-30
IL-6 reverse: 50-AGGGAATGAGGACACACCCA-30
To determine relative mRNA expression, glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used as an endogenous control. The sequences for the used primers were:
GAPDH forward: 50-CACTAGGCGCTCACTGTTCTC-30
GAPDH reverse: 50-GACTCCACGACGTACTCAGC-30
2.6. Statistical Analysis
Statistical analysis of Cq values was carried out using software R (ver. 3.0.3, R e2sCore Team,
2014) [38]. Differences between group means were estimated using one-way analysis of variance
followed by Tukey’s post hoc test, with measurements of p < 0.05 being taken as significant. In the
figures, the mean
±
standard deviation has been represented over repeats of inverse Delta Cq values
(-Delta Cq) because these reflect the behavior of the expression levels of miRNA and mRNA directly.

Nutrients 2017, 9, 215
5 of 13
3. Results
In order to dispose of both naringenin enantiomers, the resolution of commercially available
(R/S) naringenin was accomplished via preparative enantioselective chromatography employing
a Chiralpak AD-H column, as according to our previous protocol [7]. In brief, 5 g of (R/S) naringenin
was processed, yielding (S) and (R) enantiomers of naringenin in quantities and purity suitable for
an in depth biological investigation (chemical purity higher than 99%, ee > 94%).
Human Caco-2 cell cultures, a well characterized intestinal in vitro model which mimics the
intestinal barrier and allows the evaluation of the effects of naringenin following oral consumption as
a component of food, were treated with increasing concentrations (from 1 to 1000
and enantiomeric naringenin. At the highest concentration (1000 g/mL), racemate and (S) and (R)
naringenin enantiomers caused cell cytotoxicity rates of about 80%, while the lower concentrations
(1, 10, and 100 g/mL) were not cytotoxic (Figure 1). Thus, Caco-2 cell cultures were grown in the
µg/mL) of racemic
µ
µ
absence (control cell culture) and in the presence (treated cell cultures) of racemic and enantiomeric
naringenin at concentrations of 1, 10, and 100 µg/mL.
Figure 1. Survival percentage calculated against control (untreated cells) following the treatment of
Caco-2 cells with increasing concentrations (1, 10, 100 and 1000 µg/mL) of racemic naringenin and,
(R) and (S) enantiomers for 24 h. Boxes and error bars represent the mean
repeat measurements.
±
standard deviation over
To evaluate the mechanisms through which naringenin exerts its antioxidant and
anti-inflammatory activities, we determined the expression levels of miR-17-3p and miR-25-5p in
Caco-2 cell cultures treated with racemic naringenin, (S) and (R) enantiomers. Total RNA was extracted
from treated and control cell cultures, as according to the Material and Methods Section, and RT-PCR
assays were performed. The results show that cell treatment with racemic naringenin at the highest
concentration tested (100
µg/mL) induced a significant change (F = 9.459, p < 0.001) in the expression
levels of miR-17-3p, leading to it being underexpressed (Tukey, p < 0.001). (S) and (R) naringenin
enantiomers induced significant changes in miR-17-3p expression levels [(S) enantiomer: F = 28.173
p < 0.001; (R) enantiomer: F = 10.431, p < 0.001], leading to it being underexpressed at the higher
concentrations tested, in comparison with untreated cell cultures [(S)enantiomer: Tukey, p < 0.001;
(R) naringenin: Tukey, p < 0.01] (Figure 2). No statistical differences were registered (p > 0.05) between
(S) and (R) enantiomer treatments.
,

Nutrients 2017, 9, 215
6 of 13
(a)
(b)
(c)
Figure 2. Expression levels, reported as Delta Cq, of miR-17-3p in Caco-2 cells treated with increasing
concentrations of ( ) racemic naringenin, ( ) (S), and ( ) (R) naringenin (1–100 g/mL). * Indicates
a
b
c
µ
statistically significant differences between treated and untreated cell cultures, as reported in the text.
Then, we investigated the expression levels of mRNAs coding for the antioxidant enzymes,
MnSOD and GPx2, reported to be tagets of miR-17-3p. RT-PCR assays revealed that the racemate
induced an overexpression of mRNA coding for MnSOD at the concentration of 100
µg/mL,
in agreement with data obtained for miR-17-3p expression levels. Both enantiomers also induced
an overexpression of mRNA coding for MnSOD at the higher concentrations tested [(S) enantiomer:
F= 4.541, p < 0.05, Tukey, p < 0.05; (R) enantiomer: F = 105.65, p < 0.001, Tukey, p < 0.05] (Figure 3).
As far as mRNA levels coding for GPx2 are concerned, the data obtained resulted to be similar
to those obtained for mRNA coding for MnSOD (racemate: F = 75.97, p < 0.001, Tukey, p < 0.05;
(S) naringenin: F = 14.94, p < 0.05, Tukey, p < 0.05; (R) naringenin: F = 7.89 p < 0.001, Tukey, p < 0.05)
(Figure 4). No statistical differences (p > 0.05) were found between the effects of both enantiomers,
on mRNA tagets of mi-17-3p.
As far as miR-25-5p is concerned, the racemate did not induce significant miRNA variation
(data not reported). In the cases of enantiomeric naringenin treatments, miR-25-5p levels decreased in
cell cultures treated with 10 and 100 µg/mL for both enantiomers tested [(S) enantiomer: F = 3.544,
p < 0.05; Tukey, p < 0.05; (R) enantiomer: F = 2.67, p < 0.05, Tukey, p < 0.05] (Figure 5). In this case too,
no statistical differences were registered in the comparison of the treatments with the two enantiomers
(p > 0.05).

Nutrients 2017, 9, 215
7 of 13
(a)
(b)
(c)
Figure 3. Expression levels, reported as Delta Cq, of mRNA coding for MnSOD in Caco-2 cells treated
with increasing concentrations of ( ) racemic naringenin, ( ) (S), and ( ) (R) naringenin (1–100 g/mL).
a
b
c
µ
* Indicates statistically significant differences between treated and untreated cell cultures, as reported
in the text.
(a)
(b)
Figure 4. Cont.

Nutrients 2017, 9, 215
8 of 13
(c)
Figure 4. Expression levels, reported as Delta Cq, of mRNA coding for GPx2 in Caco-2 cells treated
with increasing concentrations of ( ) racemic naringin, ( ) (S), and ( ) (R) naringenin enantiomers
(1–100 g/mL). * Indicates statistically significant differences between treated and untreated cell
a
b
c
µ
cultures, as reported in the text.
(a)
(b)
Figure 5. Expression levels, reported as Delta Cq, of miR-25-5p in Caco-2 cells treated with increasing
concentrations of ( ) (S), and ( ) (R) naringenin enantiomers (1–100 g/mL). * Indicates statistically
a
b
µ
significant differences between treated and untreated cell cultures, as reported in the text.
As far as mRNA targets are concerned, the expression levels of mRNAs coding for TNF-α and
IL-6 were studied. According to the results obtained for miR-25-5p, its mRNA targets did not show
any variation in expression levels after treatment with racemate (data not reported). TNF- mRNA
expression levels were significantly decreased after (S)- and (R)-enantiomer treatments ((S)-enantiomer:
F = 21.824, p < 0.05; (R)-enantiomer: F = 264.2, p < 0.001). For the (S)-enantiomer treatment, TNF-
mRNA was underexpressed in cells treated with 10 g/mL (Tukey, p < 0.05), compared to control
cell cultures. Treatment with (R)-enantiomer gave rise to TNF- mRNA underexpression at all
concentrations tested (Tukey, p < 0.05) including the lowest concentration (1 g/mL). With regards to
the expression levels of mRNA coding for IL-6, we registered underexpression following treatment
with 1 and 10 g/mL of the (S)-enantiomer, and with 10 g/mL of the (R)-enantiomer ((S)-enantiomer:
F = 44.591, p < 0.001, Tukey, p < 0.001; (R)-enantiomer: F = 27.945, p < 0.001; Tukey, p < 0.001) (Figure 6).
α
α
µ
α
µ
µ
µ

Nutrients 2017, 9, 215
9 of 13
No statistical differences (p > 0.05) were found between the effects of (S)- and (R)-enantiomer treatment
on mRNA targets of mi-25-5p.
(a)
(b)
(c)
(d)
Figure 6. Expression levels, reported as Delta Cq, of mRNA coding for TNF-
with increasing concentrations of ( ) (S), and ( ) (R) naringenin enantiomers (1–100
IL-6 in Caco-2 cells treated with increasing concentrations of ( ) (S) and ( )(R) naringenin enantiomers
(1–100 g/mL). * Indicates statistically significant differences between treated and untreated cell
cultures, as reported in the text.
α
in Caco-2 cells treated
a
b
µg/mL) and and
c
d
µ
4. Discussion
Naringenin is a component of many plant foods commonly consumed within the diet. Therefore,
this polyphenol can be considered a common constituent of our dietary pattern. Over the last
decade, a large body of evidence suggests that naringenin exerts antioxidant and anti-inflammatory
activities in in vitro and in vivostudies. Nevertheless, the mechanism of action of this flavanone is still
largely unknown at a molecular level, as is the case for many other polyphenols. Thus, to unravel
the potential mechanism of action of naringenin, we studied its effect on the expression levels of
miRNAs involved in the endogenous antioxidant system (miR-17-3p) and inflammatory response
(miR-25-5p) in human cells. In fact, these miRNAs are known to provide additional control to the
complex regulation of gene expression at the post-transcriptional level, through the selective binding
to complementary sequences of mRNAs coding for antioxidant enzymes and pro-inflammatory
cytokines, besides other biochemical events ranging from extracellular stimuli, intracellular signaling

Nutrients 2017, 9, 215
10 of 13
pathways, and transcription factors. As far as the changes induced on miR-17-3p expression levels are
concerned, in our experimental conditions, we found that (S) and (R) naringenin possessed similar
activity, downregulating miR-17-3p from a concentration of 10 µg/mL. Racemate showed less activity,
maintaining the ability to down-regulate miR-17-3p expression at only the highest concentration.
These results seem to suggest that the enantiomers alone are more active than their equimolar mixture.
The biological significance of the modulation exerted by racemic and enantiomeric naringenin on
the expression levels of miR-17-3p has been proven by the upregulation of the expression levels of the
mRNAs coding for MnSOD and GPx2, which are reported to be validated targets of miR-17-3p [30].
In fact, in agreement with the downregulation of miR-17-3p levels, we registered an overexpression
of mRNAs coding for MnSOD and GPx2 at identical concentrations of racemic and enantiomeric
naringenin, respectively. In this case too, results obtained on mRNAs seem to suggest that the
enantiomers alone, which showed similar activity, are more active than their equimolar mixture.
The fact that the expression levels of mRNAs coding for MnSOD and GPx2 are upregulated in
response to the downregulation of miR-17-3p suggests a possible direct interaction between miRNA
and naringenin that prevents the binding of miR-17-3p to its targets, allowing to these latter to be
overexpressed. This hypothesis is in agreement with the results reported by Baselga-Escudero et al. that
demonstrated the direct binding of some polyphenols to miRNAs by means of 1H NMR spectroscopy,
suggesting a new posttranscriptional mechanism by which polyphenols could exert their modulation of
protein synthesis. In addition, no statistical differences were evidenced for both(S) and (R) enantiomers,
suggesting that the binding between miRNA and naringenin involves only the benzopyran moiety
and not the chiral center [39].
As far as miR-25-5p is concerned, both enantiomers showed the capacity to modulate its expression,
inducing the modification of the miR-25-5p expression levels only at the higher concentrations. Here
too, a decrease of activity was registered in the presence of racemic naringenin, to the extent that
no changes in the expression level of this miRNA are registered after this treatment. The expression
levels of mRNAs coding for TNF-
as in both cases we have registered an under-expression. These results suggest that miR-25-5p is
not the only miRNA involved in the modulation of TNF- and IL-6 mRNA. In fact, literature data
α and IL-6 are not in agreement with those obtained from miR-25-5p,
α
report that a single miRNA is able to bind hundreds of mRNAs, even if to date only a small fraction
of miRNA–mRNA interactions has been validated experimentally [40]. These results show that
naringenin enantiomers exert a beneficial effect regardless of their effect on the mRNA, inducing
a reduction in the gene expression of mRNA coding for TNF-α and IL-6.
Overall, the results obtained for these two latter mRNAs are consistent with those obtained
from earlier studies performed in in vivoconditions on racemic naringenin and in in vitro conditions
on naringenin enantiomers. In fact, Al-Rejaie et al. [41] showed that pretreatment with naringenin
(50 and 100 mg/kg per day), or with mesalazine (300 mg/kg per day) used as positive control,
for seven days before the induction of ulcerative colitis (through the treatment of 4% acetic acid),
decreased the levels of pro-inflammatory cytokines (i.e., TNF-α, IL-1β, and IL-6) and prostaglandin
E2. In addition, naringenin pretreatment induced an increase in catalase and superoxide dismutase at
doses of 50 and 100 mg/Kg and 100 mg/kg, respectively confirming our data regarding the antioxidant
activity. Moreover, regarding the in vitro studies, we demonstrated that in hPBMC cultures naringenin
enantiomers significantly decreased pro-inflammatory cytokine levels (i.e., TNF-α and IL-6) [7].
5. Conclusions
This study confirms the epigenetic activity of racemic naringenin and reveals the effects of racemic
and enantiomeric naringenin on the expression levels of miR-17-3p, involved in the antioxidant defense
system, and miR-25-5p, involved in the anti-inflammatory response. As far as miR-17-3p is concerned,
the downregulation of its expression levels correspond to an upregulation of mRNA coding for MnSOD
and GPx2, showing an increase in antioxidant enzyme transcriptions and therefore in the antioxidant
defense system. These findings can at least partly explain the well-known antioxidant activity of

Nutrients 2017, 9, 215
11 of 13
naringenin and, for the first time, show that this property is exerted through an epigenetic mechanism.
As far as miR-25-5p is concerned, the underexpression of mRNA coding for the two cytokines, TNF-
α
and IL-6, is not supported by its behavior. This suggests that the modulation of these two mRNAs is
not strictly under the control of miR-25-5p, and that this miRNA could act with other miRNAs, giving
rise to synergistic and/or antagonistic effects.
Moreover, both naringeninenantiomers were found to be equally active on miRNAs at a higher
level than the racemate, causing down-regulation in both cases, suggesting a negative synergism
between enantiomers. (S) and (R) naringenin showed different activity on target mRNAs, suggesting
that other epigenetic mechanisms (other miRNAs, DNA methylations, histone protein modifications)
could be involved in the expression of the tested mRNAs. In addition, it seems to suggest that the
mechanisms underlying these interactions, enantiomer–miRNA and enantiomer–mRNA, are different.
Thus, further studies are needed to understand in what way naringenin and its enantiomers are able
to modulate levels of miRNA, through both direct and indirect interaction.
In conclusion, our results show the role of naringenin (both racemic and enantiomeric) as
antioxidant agent acting through an epigenetic mechanism of action and support the hypothesis
that long-term consumption of foods rich in naringenin could counteract oxidative stress through
the increase of enzymatic antioxidant defense. The growing body of evidence demonstrating the
antioxidant activity of naringenin as well asthese results lead to expect that naringenin could
actually exert antioxidant effects also in vivo. Accordingly, in vivoinvestigations are needed for
future applications of naringenin as an antioxidant agent in functional foods or food supplements.
Acknowledgments: The authors would like to thank Michele Ghitti for his excellent statistical data analysis
throughout this study.
Author Contributions: M.D., S.C. and E.C. conceived and designed the experiments; E.C. performed the
cell cultures; V.C. and A.D.L. performed miRNA and mRNA expression assays; D.R. and E.M. performed
naringenin enantioresolution; and M.D. and V.C. wrote the paper. All authors revised the paper and approved the
final manuscript.
Conflicts of Interest: The authors have declared no conflict of interest.
References
1.
2.
3.
Patel, K.; Singh, G.K.; Patel, D.K. Review on pharmacological and analytical aspects of naringenin. Chin. J.
Integr. Med. 2014, 14, 1–13. [CrossRef] [PubMed]
Bugianesi, R.; Catasta, G.; Spigno, P.; D’Uva, A.; Maiani, G. Naringenin from cooked tomato paste is
bioavailable in men. J. Nutr. 2002, 132, 3349–3352. [PubMed]
Vallverdu’-Queralt, A.; Jauregui, O.; Medina-Remon, A.; Andres-Lacueva, C; Lamuela-Raventos, R.M.
Improved characterization of tomato polyphenols using liquid chromatography/electrospray ionization
linear ion trap quadrupole Orbitrap mass spectrometry and liquid chromatography/electrospray ionization
tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2010, 24, 2986–2992. [CrossRef] [PubMed]
Ho, P.C.; Saville, D.J.; Coville, P.F.; Wanwimolruk, S. Content of CYP3A4 inhibitors, naringin, naringenin and
bergapten in grapefruit and grapefruit juice products. Pharm. Acta Helv. 2000, 74, 379–385. [CrossRef]
Tomas-Barberen, F.A.; Clifford, M.N. Flavanones, chalcones and dihydrochalcones—Nature, occurrence and
dietary burden. J. Sci. Food Agric. 2000, 80, 1073–1080. [CrossRef]
Orhan, I.E.; Nabavi, S.F.; Daglia, M.; Tenore, G.C.; Mansouri, K.; Nabavi, S.M. Naringenin and atherosclerosis:
A review of literature. Curr. Pharm. Biotechnol. 2015, 16, 245–251. [CrossRef] [PubMed]
Gaggeri, R.; Rossi, D.; Daglia, M.; Leoni, F.; Avanzini, M.A.; Mantelli, M.; Juza, M.; Collina, S. An eco-friendly
enantioselective access to (R)-naringenin as inhibitor of proinflammatory cytokine release. Chem. Biodivers.
2013, 10, 1531–1538. [CrossRef] [PubMed]
4.
5.
6.
7.
8.
Gaggeri, R.; Rossi, D.; Christodoulou, M.S.; Passarella, D.; Leoni, F.; Azzolina, O.; Collina, S. Chiral
flavanones from AmygdaluslycioidesSpach: Structural elucidation and identification of TNFalpha inhibitors
by bioactivity-guided fractionation. Molecules 2012, 17, 1665–1674. [CrossRef] [PubMed]

Nutrients 2017, 9, 215
12 of 13
9.
Song, H.M.; Park, G.H.; Eo, H.J.; Lee, J.W.; Kim, M.K.; Lee, J.R.; Lee, M.H.; Koo, J.S.; Jeong, J.B.
Anti-Proliferative Effect of Naringenin through p38-Dependent Downregulation of Cyclin D1 in Human
Colorectal Cancer Cells. Biomol. Ther. (Seoul) 2015, 23, 339–344. [CrossRef] [PubMed]
10. Wilcox, L.J.; Borradaile, N.M.; Huff, M.W. Antiatherogenic properties of naringenin, a citrus flavonoid.
Cardiovasc. Drug Rev. 1999, 17, 160–178. [CrossRef]
11. Erlund, I.; Meririnne, E.; Alfthan, G.; Aro, A. Plasma kinetics and urinary excretion of the flavanones
naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J. Nutr. 2001, 131,
235–241. [PubMed]
12. Manach, C.; Morand, C.; Gil-Izquierdo, A.; Bouteloup-Demange, C.; Re’mesy, C. Bioavailability in humans
of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur. J. Clin. Nutr.
2003, 57, 235–242. [CrossRef] [PubMed]
13. Manach, C.; Scalbert, A.; Morand, C.; Rémésy, C.; Jiménez, L. Polyphenols: Food sources and bioavailability.
Am. J. Clin. Nutr. 2004, 79, 727–747. [PubMed]
14. Felgines, C.; Texier, O.; Morand, C.; Manach, C.; Scalbert, A.; Régerat, F.; Rémésy, C. Bioavailability of
the flavanone naringenin and its glycosides in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279,
G1148–G1154. [PubMed]
15. Orrego-Lagarón, N.; Martínez-Huélamo, M.; Vallverdú-Queralt, A.; Lamuela-Raventos, R.M.;
Escribano-Ferrer, E. High gastrointestinal permeability and local metabolism of naringenin: Influence
of antibiotic treatment on absorption and metabolism. Br. J. Nutr. 2015, 114, 169–180. [CrossRef] [PubMed]
16. Chtourou, Y.; Kamoun, Z.; Zarrouk, W.; Kebieche, M.; Kallel, C.; Gdoura, R.; Fetoui, H. Naringenin
ameliorates renal and platelet purinergic signalling alterations in high-cholesterol fed rats through the
suppression of ROS and NF-κB signaling pathways. Food Funct. 2016, 7, 183–193. [CrossRef] [PubMed]
17. Ozkaya, A.; Sahin, Z.; Dag, U.; Ozkaraca, M. Effects of Naringenin on Oxidative Stress and Histopathological
Changes in the Liver of Lead Acetate Administered Rats. J. Biochem. Mol. Toxicol. 2016, 30, 243–248.
[CrossRef] [PubMed]
18. Liu, Y.; An, W.; Gao, A. Protective effects of naringenin in cardiorenal syndrome. J. Surg. Res. 2016, 203,
416–423. [CrossRef]
19. Chtourou, Y.; Fetoui, H.; Jemai, R.; Ben Slima, A.; Makni, M.; Gdoura, R. Naringenin reduces
cholesterol-induced hepatic inflammation in rats by modulating matrix metalloproteinases-2, 9 via inhibition
of nuclear factor κB pathway. Eur. J. Pharmacol. 2015, 746, 96–105. [CrossRef] [PubMed]
20. Azuma, T.; Shigeshiro, M.; Kodama, M.; Tanabe, S.; Suzuki, T. Supplemental naringenin prevents intestinal
barrier defects and inflammation in colitic mice. J. Nutr. 2013, 143, 827–834. [CrossRef] [PubMed]
21. Dou, W.; Zhang, J.; Sun, A.; Zhang, E.; Ding, L.; Mukherjee, S.; Wei, X.; Chou, G.; Wang, Z.T.;
Mani, S. Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor
4/NF-κBsignalling. Br. J. Nutr. 2013, 110, 599–608. [CrossRef] [PubMed]
22. Blade, C.; Baselga-Escudero, L.; Arola-Arnal, A. microRNAs as new targets of dietary polyphenols.
Curr. Pharm. Biotechnol. 2014, 15, 343–351. [CrossRef] [PubMed]
23. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297. [CrossRef]
24. Wu, X.; Tan, X.; Fu, S.W. May Circulating microRNAs be Gastric Cancer Diagnostic Biomarkers? J. Cancer
2015, 6, 1206–1213. [CrossRef] [PubMed]
25. Fu, X.M.; Zhou, Y.Z.; Cheng, Z.; Liao, X.B.; Zhou, X.M. MicroRNAs: Novel Players in Aortic Aneurysm.
BioMed Res. Int. 2015, 2015, 831641. [CrossRef] [PubMed]
26. Femminella, G.D.; Ferrara, N.; Rengo, G. The emerging role of microRNAs in Alzheimer’s disease.
Front. Physiol. 2015, 12, 6–40. [CrossRef] [PubMed]
27. Yanaihara, N.; Caplen, N.; Bowman, E.; Seike, M.; Kumamoto, K.; Yi, M.; Stephens, R.M.; Okamoto, A.;
Yokota, J.; Tanaka, T.; et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.
Cancer Cell 2006, 9, 189–198. [CrossRef] [PubMed]
28. Iorio, M.V.; Ferracin, M.; Liu, C.G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.;
Campiglio, M.; et al. MicroRNA gene expression deregulation in human breastcancer. Cancer Res. 2005, 65,
7065–7070. [CrossRef] [PubMed]
29. Ozen, M.; Creighton, C.J.; Ozdemir, M.; Ittmann, M. Widespread deregulation of microRNA expression in
human prostate cancer. Oncogene 2008, 27, 1788–1793. [CrossRef] [PubMed]

Nutrients 2017, 9, 215
13 of 13
30. Xu, Y.; Fang, F.; Zhang, J.; Josson, S.; St Clair, W.H.; St Clair, D.K. miR-17* suppresses tumorigenicity of
prostate cancer by inhibiting mitochondrial antioxidant enzymes. PLoS ONE 2010, 5, e14356. [CrossRef]
[PubMed]
31. Tili, E.; Michaille, J.J.; Alder, H.; Volinia, S.; Delmas, D.; Latruffe, N.; Croce, C.M. Resveratrol modulates the
levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFβ signaling pathway
in SW480 cells. Biochem. Pharmacol. 2010, 80, 2057–2065. [CrossRef] [PubMed]
32. Lesjak, M.; Hoque, R.; Balesaria, S.; Skinner, V.; Debnam, E.S.; Surjit, K.S.; Srai, S.K.; Sharp, P.A. Quercetin
inhibits intestinal iron absorption and ferroportin transporter expression in vivo and in vitro. PLoS ONE
2014, 9, e102900. [CrossRef] [PubMed]
33. Curti, V.; Capelli, E.; Boschi, F.; Nabavi, S.F.; Bongiorno, A.I.; Habtemariam, S.; Nabavi, S.M.; Daglia, M.
Modulation of human miR-17-3p expression by methyl 3-O-methyl gallate as explanation of its in vivo
protective activities. Mol. Nutr. Food Res. 2014, 58, 1776–1784. [CrossRef] [PubMed]
34. Nabavi, S.M.; Habtemariam, S.; Nabavi, S.F.; Sureda, A.; Daglia, M.; Moghaddam, A.H.; Amani, M.A.
Protective effect of gallic acid isolated from Peltiphyllumpeltatum against sodium fluoride-induced oxidative
stress in rat’s kidney. Mol. Cell. Biochem. 2013, 372, 233–239. [CrossRef] [PubMed]
35. Lee, T.W.; Tan, E.L.; Ng, C.C.; Gan, S.Y. The Effect of Cytokines on MicroRNA Expression in TW01
Nasopharyngeal Carcinoma Cells. Br. J. Med. Med. Res. 2013, 3, 543–554. [CrossRef]
36. Mei, Z.; Chen, S.; Chen, C.; Xiao, B.; Li, F.; Wang, Y.; Tao, Z. Interleukin-23 Facilitates Thyroid Cancer Cell
Migration and Invasion by Inhibiting SOCS4 Expression via MicroRNA-25. PLoS ONE 2015, 10, e0139456.
[CrossRef]
37. Milenkovic, D.; Deval, C.; Gouranton, E.; Landrier, J.F.; Scalbert, A.; Morand, C.; Mazur, A. Modulation
of miRNA expression by dietary polyphenols in apoE deficient mice: A new mechanism of the action of
polyphenols. PLoS ONE 2012, 7, e29837. [CrossRef]
38. R Core Team. R: A language and Environment for Statistical Computing, R Foundation for Statistical
Computing, Vienna, Austria. 2014. Available online: http://www.R-project.org/ (accessed on 30 July 2016).
39. Baselga-Escudero, L.; Blade, C.; Ribas-Latre, A.; Casanova, E.; Suárez, M.; Torres, J.L.; Salvadó, M.J.; Arola, L.;
Arola-Arnal, A. Resveratrol and EGCG bind directly and distinctively to miR-33a and miR-122 and modulate
divergently their levels in hepatic cells. Nucleic Acids Res. 2014, 42, 882–892. [CrossRef] [PubMed]
40. Helwak, A.; Kudla, G.; Dudnakova, T.; Tollervey, D. Mapping the Human miRNA Interactome by CLASH
Reveals Frequent Noncanonical Binding. Cell 2013, 153, 654–665. [CrossRef] [PubMed]
41. Al-Rejaie, S.S.; Abuohashish, H.M.; Al-Enazi, M.M.; Al-Assaf, A.H.; Parmar, M.Y.; Ahmed, M.M.
Protectiveeffect of naringenin on acetic acid-induced ulcerative colitis in rats. World J. Gastroenterol. 2013, 19,
5633–5644. [CrossRef] [PubMed]
©
2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).